

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIG. 1

SAHA Patient: IV vs ORAL (200 mg/dose)




FIG. 2

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)




FIG. 3




FIG. 4

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)




FIG. 5




FIG. 6




FIG. 7

Protocol 01-021
(ORAL SAHA)
ARM A: SOLID
TUMOR PATIENTS
Cohort IIa (400 mg/dose)






FIG. 8

SAHA Patients: ORAL/Cohort II (400 mg/dose)






FIG. 9A
Oral 200 mg vs. 400 mg (Fasting)
Oral dose on Cycle 1 Day 8

FIG. 9B

Oral 200 mg vs. 400 mg (no-fasting)

Oral Dose on Cycle 1 Day 9




FIG. 9C

IV 200 mg vs. 400 mg
IV Dose on Cycle 1 Day 1




FIG. 10

Apparent Half-life of the Oral Dose
Half-life




FIG. 11

AUC of the Oral
Dose AUC_{last}




FIG. 12

Bioavailability after 200 and 400 mg by Day





FIG. 13A

CTCL Patient 001 (MD Anderson)

Baseline



After 1 Week of SAHA





FIG. 13B

CTCL Patient 001 (MD Anderson)

Baseline



After 1 Week of SAHA





FIG. 13C

CTCL Patient (MDACC)

Baseline




After 8 weeks of SAHA



FIG. 13D

CTCL Patient 008 (MD Anderson)

Baseline



After 8 weeks of SAHA




FIG. 14

Metastatic Laryngeal Cancer (MSKCC)

Pre-treatment



After 8 weeks of treatment

